

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

## Natural Polymorphisms in *Mycobacterium tuberculosis* Conferring Resistance to Delamanid in Drug-naïve Patients

Martina L. Reichmuth,<sup>a\*</sup> Rico Hoemke,<sup>b,c\*</sup> Kathrin Zürcher,<sup>a</sup> Peter Sander,<sup>b,c</sup> Anchalee Avihingsanon,<sup>d</sup> Jimena Collantes,<sup>e</sup> Chloé Loiseau,<sup>f,g</sup> Sonia Borrell,<sup>f,g</sup> Miriam Reinhard,<sup>f,g</sup> Robert J. Wilkinson,<sup>h,i,j</sup> Marcel Yotebieng,<sup>k,l</sup> Lukas Fenner,<sup>a</sup> Erik C. Böttger,<sup>b,c</sup> Sebastien Gagneux,<sup>f,g</sup> Matthias Egger,<sup>a,m</sup> Peter M. Keller,<sup>b,c,n</sup> on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA)

- a) Institute of Social and Preventive Medicine, University of Bern, Bern Switzerland
- b) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
- c) Swiss National Center for Mycobacteria, Zurich, Switzerland
- d) The HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Centre and Tuberculosis research unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- e) Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru
- f) Swiss Tropical and Public Health Institute, Basel, Switzerland
- g) University of Basel, Basel, Switzerland
- h) Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Republic of South Africa
- i) Department of Infectious Diseases, Imperial College, London, UK
- j) The Francis Crick Institute, London, UK
- k) National TB Lab, Kinshasa, Democratic Republic of the Congo (DRC)
- l) Albert Einstein College of Medicine, New York, USA
- m) Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, Republic of South Africa
- n) Institute for Infectious Diseases, University of Bern, Bern, Switzerland

\* Martina L. Reichmuth and Rico Hoemke contributed equally to this work.

Correspondence to:

Peter M. Keller, MD

Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, 3001 Bern, Switzerland

[peter.keller@ifik.unibe.ch](mailto:peter.keller@ifik.unibe.ch), Phone +41 31 632 35 62

41 **ABSTRACT**

42

43 Mutations in the genes of the F<sub>420</sub> signaling pathway, including *dnn*, *fgd1*, *fbiA*, *fbiB*, *fbiC*, and *fbiD*, of  
44 *Mycobacterium tuberculosis* (*Mtb*) complex can lead to delamanid resistance. We searched for such  
45 mutations among 129 *Mtb* strains from Asia, South-America, and Africa using whole-genome  
46 sequencing; 70 (54%) strains had at least one mutation in one of the genes. For ten strains with  
47 mutations, we determined the minimum inhibitory concentration (MIC) of delamanid. We found one  
48 strain from a delamanid-naïve patient carrying the natural polymorphism Tyr29del (*ddn*) that was  
49 associated with a critical MIC to delamanid.

50

51

52

53 **Keywords:** *Mycobacterium tuberculosis*, delamanid, resistance, mutations

54

55 **Word counts:** Abstract 94 words, main text 1098 words, 36 references, 1 table, 2 supplementary  
56 material.

57

58 In 2014, the new anti-tuberculosis (TB) drug, delamanid (also known as OPC-67683 or Deltyba™) was  
59 introduced (1). The World Health Organisation (WHO) recommends the administration of delamanid if  
60 a standard effective drug regimen cannot be prescribed due to drug toxicity or resistance (2, 3). Thus,  
61 the European Medicines Agency (EMA) conditionally approved delamanid for the treatment of  
62 multidrug-resistant (MDR) TB (1, 3, 4). Of note, six years after its market launch, robust and widely  
63 accepted breakpoints that define susceptibility and resistance to delamanid still do not exist (5). The  
64 few available studies suggest a critical MIC between 0.125 mg/L and 0.2 mg/L, and an Epidemiological  
65 Cutoff Value (ECOFF) of 0.04 mg/L (6-9). This ECOFF is in line with the WHO (10).

66  
67 Delamanid is a drug of the bicyclic nitroimidazole class with potent anti-TB activity (1, 11). It is a pro-  
68 drug which is activated by the deazaflavin (F<sub>420</sub>) dependent nitroreductase (*ddn*) through hydride  
69 transfer, forming unstable intermediates, which in turn lead to the formation of reactive nitrogen species  
70 (nitric oxide, nitrous acid) (12, 13). Activated delamanid thus has a dual bactericidal mode of action as  
71 the primary decomposition product prevents mycolic acid synthesis while the reactive nitrogen species  
72 cause respiratory poisoning (12-15). Loss of function mutations in *ddn* or one of the five coenzymes  
73 (*fgd1*, *fbiA*, *fbiB*, *fbiC*, and *fbiD*) have been proposed as a mechanism of resistance to delamanid (12,  
74 13, 16, 17). *In vitro*, frequencies of delamanid resistance-conferring mutations in the *Mycobacterium*  
75 *tuberculosis* (*Mtb*) laboratory strain *H37Rv* and in *M. bovis* range from  $2.51 \times 10^{-5}$  to  $6.44 \times 10^{-6}$  (13).  
76 Previous studies have found several resistance-conferring mutations, including Leu107Pro (*ddn*), 51-  
77 101del (*ddn*), Trp88STOP (*ddn*), Gly81Asp (*ddn*), Gly81Ser (*ddn*), Gly53Asp (*ddn*), c.146\_147insC  
78 (*fgd1*), Gln88Glu (*fgd1*), Lys250STOP (*fbiA*), Arg175His (*fbiA*), and Val318Ile (*fbiC*) (6-8, 18-22).

79  
80 This multicentre study has been described in detail elsewhere and is part of the International  
81 epidemiology Databases to Evaluate AIDS (IeDEA) (23). We identified putative delamanid resistance-  
82 conferring mutations in *Mtb* strains from TB patients living with HIV (PLWH) and HIV negative TB  
83 patients naïve to delamanid using whole-genome sequencing (WGS) and MIC determination. We  
84 collected demographic and clinical characteristics of patients that were recruited between 2013-2016  
85 in Peru, Thailand, Côte d'Ivoire, Democratic Republic of the Congo (DRC), Kenya, and South Africa  
86 (24, 25). The Cantonal Ethics Committee in Bern, Switzerland, and local institutional review boards  
87 approved the study. Written informed consent was obtained at all locations, except in South Africa,  
88 where consent was not required for archived samples.

89  
90 The sequencing pipeline has been described previously (25). In brief, *Mtb* DNA was extracted and  
91 sequenced using Illumina HiSeq 2500 (Illumina, San Diego, CA, USA). For the analysis, we used the  
92 well-established pipeline TBProfiler (<https://github.com/jodyphelan/TBProfiler> (26, 27)). It aligns short  
93 reads to the *Mtb* reference (H37Rv: NC\_000962.3) with bowtie2 v2.3.5, BWA v0.7.17 or minimap2  
94 v2.16 and then calls variants with SAMtools v1.9 (28-31). To identify putative delamanid resistance-  
95 conferring mutations, we analysed F<sub>420</sub> genes (*ddn*, *fgd1*, *fbiA*, *fbiB*, *fbiC*, and *fbiD*) with variant  
96 frequencies  $\geq 75\%$ . A subset of *Mtb* strains with at least one mutation in F<sub>420</sub> genes were re-cultured in

97 liquid medium and subjected to delamanid MIC determination ([Supplementary Figure 1](#)). We assumed  
98 that 0.04 mg/L indicates a critical MIC (9).

99

100 We included 129 *Mtb* isolates among them 52 (40.3%) from Peru, 14 (10.9%) from Thailand, 51 (39.5%)  
101 from Côte d'Ivoire, 14 (10.9%) from DRC, and 1 (0.8%) each from Kenya and South Africa. We identified  
102 70 (54.3%) isolates with polymorphisms in at least one of the six  $F_{420}$  genes as compared to the  
103 reference genome ([Supplementary Table 1](#)). None of the patients infected with either of these strains  
104 had a history of TB and all were naïve to delamanid. We selected strains fulfilling the following criteria:  
105 i) mutations in a part of the gene encoding regions of catalytic or structural importance predicted by  
106 ARIBA and then the PhyResSE pipeline (32, 33), ii) culture of the strain available iii) bacterial growth  
107 amenable to microdilution (25). MIC determination was performed on ten isolates with mutations in the  
108  $F_{420}$  genes. Four isolates showed a MIC >0.015 mg/L: 0.5 (patient 1), 0.03 (patients 6 and 10), and >8  
109 mg/L (patient 9; [Table 1](#); [Supplementary Figure 1](#)). The isolate from patient 1 had a polymorphism in  
110 *fgd1* (Lys270Met), was susceptible to the six tested drugs (isoniazid, rifampicin, ethambutol,  
111 pyrazinamide, moxifloxacin, and amikacin). The patient was cured. The isolate from patient 9 had two  
112 alterations, a deletion in *ddn* (Tyr29del) and carried a nucleotide change in *fgd1* (T960C). The strain  
113 showed an elevated delamanid MIC and was phenotypically susceptible to six other drugs tested. The  
114 patient died. Isolates of patient 10 (and 6) had a MIC above 0.015 but below 0.04 mg/L ([Table 1](#)). This  
115 suggests a low-level resistance to delamanid (22), which could be due to the combination of various  
116 mutations: Ala416Val (*fbtC*), Trp678Gly (*fbtC*), Arg64Ser (*fgd1*), and T960C (*fgd1*).

117

118 In summary, in the subset of ten isolates with polymorphisms in the six targeted genes, six had no  
119 elevated MIC in the microdultion, while four isolates had ([Table 1](#)). In line with previous studies, we  
120 found that Lys270Met in *fgd1* is a natural polymorphism characteristic of *Mtb* lineage 4.1.2.1, which  
121 may (patient 1 and 6) or may not (patient 7) lead to an increased delamanid MIC (19, 34, 35). All 16  
122 strains of lineage 4.1.2.1 showed this lineage-specific marker ([Supplementary Table 1](#)). Furthermore,  
123 T960C (*fgd1*) is a synonymous substitution and was found in three other patient isolates which  
124 expectedly did not have a critical MIC. The increase in the delamanid MIC in the isolate of patient 9 was  
125 due to the deletion in *ddn* (7). Our results thus suggest that Tyr29del is a natural polymorphism leading  
126 to an increased delamanid MIC. Our study was too small to estimate the prevalence of strains that are  
127 naturally resistant to delamanid. Lee et al. 2020, screened 14,876 *Mtb* strains and found two strains  
128 with Tyr29del, for a prevalence of 0.013% (36). However, in their study, only the *ddn* gene was screened  
129 and the prevalence of natural resistance could, therefore, be higher.

130

131 In conclusion, we confirm that mutations in  $F_{420}$  genes can confer an elevated delamanid MIC (13, 19).  
132 Whether our findings also apply to the related drug pretomanid should be investigated in future studies.  
133 The occurrence of clinical *Mtb* isolates with naturally elevated MICs to delamanid from previously  
134 untreated patients calls for careful drug susceptibility testing (DST) prior to delamanid treatment (5, 36).  
135 However, access to DST is limited in high burden countries. This dilemma highlights the conflict

136 between making new drugs available in high-burden countries and avoiding spread of drug-resistant  
137 strains.  
138

139 **Data availability.** WGS data from patients *Mtb* strains shown in Table 1 have been submitted to the  
140 NCBI (PRJNA300846; [Supplementary Table 1](#)).

141

## 142 **ACKNOWLEDGMENTS**

143 We thank all sites that participated, patients whose data were used in this study and Marie Ballif for  
144 contributing to the data collection and for critically reading the manuscript. Calculations were performed  
145 on UBELIX (<http://www.id.unibe.ch/hpc>), the HPC cluster at the University of Bern.

146

## 147 **ROLE OF FUNDING SOURCE**

148 This research was supported by the Swiss National Foundation (project grant numbers 153442,  
149 310030\_166687, 310030\_188888, IZRJZ3\_164171, IZLSZ3\_170834 and CRSII5\_177163). The  
150 International Epidemiology Databases to Evaluate AIDS (IeDEA) is supported by the U.S. National  
151 Institutes of Health's, National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver  
152 National Institute of Child Health and Human Development, the National Cancer Institute, the National  
153 Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood  
154 Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and  
155 Digestive and Kidney Diseases, the Fogarty International Center, and the National Library of Medicine:  
156 Asia- Pacific, U01AI069907; CCASAnet, U01AI069923; Central Africa, U01AI096299; East Africa,  
157 U01AI069911; NA-ACCORD, U01AI069918; Southern Africa, U01AI069924; West Africa,  
158 U01AI069919. RJW receives support from the Francis Crick Institute, which is funded by UKRI, CRUK,  
159 and Wellcome (FC0010218, 104803, 203135). This work is solely the responsibility of the authors and  
160 does not necessarily represent the official views of any of the institutions mentioned above. This  
161 manuscript is not peer-reviewed.

162

## 163 **CONFLICT OF INTEREST**

164 Authors have nothing to disclose.

165

166 REFERENCE

- 167 1. Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J. 2018.  
168 Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).  
169 Tuberculosis (Edinb) 111:20-30.
- 170 2. Esmail A, Sabur NF, Okpechi I, Dheda K. 2018. Management of drug-resistant tuberculosis in  
171 special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-  
172 specific dysfunction, and in the critically ill. J Thorac Dis 10:3102-3118.
- 173 3. WHO. Consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health  
174 Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
- 175 4. EMA. 2018. Deltyba (delamanid): An overview of Deltyba and why it is authorised in the EU.  
176 Agency EM, London, United Kingdom.
- 177 5. Koser CU, Maurer FP, Kranzer K. 2019. 'Those who cannot remember the past are condemned  
178 to repeat it': Drug-susceptibility testing for bedaquiline and delamanid. Int J Infect Dis 80S:S32-  
179 S35.
- 180 6. Stinson K, Kurepina N, Venter A, Fujiwara M, Kawasaki M, Timm J, Shashkina E, Kreiswirth  
181 BN, Liu Y, Matsumoto M, Geiter L. 2016. MIC of Delamanid (OPC-67683) against  
182 Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration. Antimicrob  
183 Agents Chemother 60:3316-22.
- 184 7. Schena E, Nedialkova L, Borroni E, Battaglia S, Cabibbe AM, Niemann S, Utpatel C, Merker  
185 M, Trovato A, Hofmann-Thiel S, Hoffmann H, Cirillo DM. 2016. Delamanid susceptibility testing  
186 of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960  
187 system. J Antimicrob Chemother 71:1532-9.
- 188 8. Hoffmann H, Kohl TA, Hofmann-Thiel S, Merker M, Beckert P, Jatou K, Nedialkova L,  
189 Sahalchik E, Rothe T, Keller PM, Niemann S. 2016. Delamanid and Bedaquiline Resistance  
190 in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant  
191 Tuberculosis in a Tibetan Refugee. Am J Respir Crit Care Med 193:337-40.
- 192 9. Keller PM, Homke R, Ritter C, Valsesia G, Bloemberg GV, Bottger EC. 2015. Determination of  
193 MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in  
194 Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST. Antimicrob  
195 Agents Chemother 59:4352-5.
- 196 10. WHO. Technical Report on critical concentrations for drug susceptibility testing of medicines  
197 used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2018  
198 (WHO/CDS/TB/2018.5). Licence: CC BY-NC-SA 3.0 IGO.
- 199 11. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa  
200 Y, Komatsu M. 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising  
201 action against tuberculosis in vitro and in mice. PLoS Med 3:e466.
- 202 12. Purwantini E, Mukhopadhyay B. 2009. Conversion of NO<sub>2</sub> to NO by reduced coenzyme F420  
203 protects mycobacteria from nitrosative damage. Proc Natl Acad Sci U S A 106:6333-8.
- 204 13. Fujiwara M, Kawasaki M, Hariguchi N, Liu Y, Matsumoto M. 2018. Mechanisms of resistance  
205 to delamanid, a drug for Mycobacterium tuberculosis. Tuberculosis (Edinb) 108:186-194.
- 206 14. Greening C, Ahmed FH, Mohamed AE, Lee BM, Pandey G, Warden AC, Scott C, Oakeshott  
207 JG, Taylor MC, Jackson CJ. 2016. Physiology, Biochemistry, and Applications of F420- and  
208 Fo-Dependent Redox Reactions. Microbiol Mol Biol Rev 80:451-93.



- 209 15. Van den Bossche A, Varet H, Sury A, Sismeiro O, Legendre R, Coppee JY, Mathys V,  
210 Ceysens PJ. 2019. Transcriptional profiling of a laboratory and clinical *Mycobacterium*  
211 tuberculosis strain suggests respiratory poisoning upon exposure to delamanid. *Tuberculosis*  
212 (Edinb) 117:18-23.
- 213 16. Rifat D, Li S-Y, Ioerger T, Lanoix J-P, Lee J, Bashiri G, Sacchettini J, Nuermberger E. 2018.  
214 Mutations in Rv2983 as a novel determinant of resistance to nitroimidazole drugs in  
215 *Mycobacterium tuberculosis*. *bioRxiv preprint doi:10.1101/457754*.
- 216 17. Bashiri G, Antoney J, Jirgis ENM, Shah MV, Ney B, Copp J, Stuteley SM, Sreebhavan S,  
217 Palmer B, Middleditch M, Tokuriki N, Greening C, Scott C, Baker EN, Jackson CJ. 2019. A  
218 revised biosynthetic pathway for the cofactor F420 in prokaryotes. *Nat Commun* 10:1558.
- 219 18. Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T,  
220 Homke R, Ritter C, Feldmann J, Schulthess B, Gagneux S, Bottger EC. 2015. Acquired  
221 Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. *N Engl J Med* 373:1986-  
222 8.
- 223 19. Feuerriegel S, Koser CU, Bau D, Rusch-Gerdes S, Summers DK, Archer JA, Marti-Renom MA,  
224 Niemann S. 2011. Impact of Fgd1 and *ddn* diversity in *Mycobacterium tuberculosis* complex on  
225 *in vitro* susceptibility to PA-824. *Antimicrob Agents Chemother* 55:5718-22.
- 226 20. Yang JS, Kim KJ, Choi H, Lee SH. 2018. Delamanid, Bedaquiline, and Linezolid Minimum  
227 Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-  
228 resistant and Extensively Drug-resistant Tuberculosis in Korea. *Ann Lab Med* 38:563-568.
- 229 21. Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, Li Y, Zhao L, Fu Y, Huang H. 2017. *In Vitro*  
230 Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and  
231 Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. *Antimicrob*  
232 *Agents Chemother* 61.
- 233 22. Polsfuss S, Hofmann-Thiel S, Merker M, Krieger D, Niemann S, Russmann H, Schonfeld N,  
234 Hoffmann H, Kranzer K. 2019. Emergence of Low-level Delamanid and Bedaquiline Resistance  
235 During Extremely Drug-resistant Tuberculosis Treatment. *Clin Infect Dis* 69:1229-1231.
- 236 23. Antiretroviral Therapy in Low-Income Countries Collaboration of the International  
237 epidemiological Databases to Evaluate A, Collaboration ARTC, Brinkhof MW, Egger M, Boule  
238 A, May M, Hosseinipour M, Sprinz E, Braitstein P, Dabis F, Reiss P, Bangsberg DR,  
239 Rickenbach M, Miro JM, Myer L, Mocroft A, Nash D, Keiser O, Pascoe M, van der Borgh S,  
240 Schechter M. 2007. Tuberculosis after initiation of antiretroviral therapy in low-income and high-  
241 income countries. *Clin Infect Dis* 45:1518-21.
- 242 24. Zürcher K, Ballif M, Fenner L, Borrell S, Keller PM, Gnokoro J, Marcy O, Yotebieng M, Diero L,  
243 Carter EJ, Rockwood N, Wilkinson RJ, Cox H, Ezati N, Abimiku AIG, Collantes J, Avihingsanon  
244 A, Kawkitinarong K, Reinhard M, Hömke R, Huebner R, Gagneux S, Böttger EC, Egger M,  
245 Zürcher K, Egger M, Fenner L, Ballif M, Chammartin F, Gagneux S, Borrell S, Reinhard M,  
246 Boettger EC, Keller P, Hömke R, Abimiku AI, Ezati N, Yotebieng M, Wenzli L, Tabala M, Cox H,  
247 Rockwood N, Warren R, Streicher E, Wilkinson RJ, Carter EJ, Diero L, Collantes J, Zamudio  
248 C, Huebner R, et al. 2019. Drug susceptibility testing and mortality in patients treated for  
249 tuberculosis in high-burden countries: a multicentre cohort study. *The Lancet Infectious*  
250 *Diseases* 19:298-307.
- 251 25. Gygli SM, Keller PM, Ballif M, Blochliger N, Homke R, Reinhard M, Loiseau C, Ritter C, Sander  
252 P, Borrell S, Collantes Loo J, Avihingsanon A, Gnokoro J, Yotebieng M, Egger M, Gagneux S,  
253 Bottger EC. 2019. Whole-Genome Sequencing for Drug Resistance Profile Prediction in  
254 *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 63.
- 255 26. Phelan JE, O'Sullivan DM, Machado D, Ramos J, Opong YEA, Campino S, O'Grady J,  
256 McNerney R, Hibberd ML, Viveiros M, Huggett JF, Clark TG. 2019. Integrating informatics tools

- 257 and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs.  
258 *Genome Med* 11:41.
- 259 27. Coll F, Phelan J, Hill-Cawthorne GA, Nair MB, Mallard K, Ali S, Abdallah AM, Alghamdi S,  
260 Alsomali M, Ahmed AO, Portelli S, Oppong Y, Alves A, Bessa TB, Campino S, Caws M,  
261 Chatterjee A, Crampin AC, Dheda K, Furnham N, Glynn JR, Grandjean L, Minh Ha D, Hasan  
262 R, Hasan Z, Hibberd ML, Joloba M, Jones-Lopez EC, Matsumoto T, Miranda A, Moore DJ,  
263 Mocillo N, Panaiotov S, Parkhill J, Penha C, Perdigao J, Portugal I, Rchiad Z, Robledo J, Sheen  
264 P, Shesha NT, Sirgel FA, Sola C, Oliveira Sousa E, Streicher EM, Helden PV, Viveiros M,  
265 Warren RM, McNerney R, Pain A, et al. 2018. Genome-wide analysis of multi- and extensively  
266 drug-resistant *Mycobacterium tuberculosis*. *Nat Genet* 50:307-316.
- 267 28. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform.  
268 *Bioinformatics* 25:1754-60.
- 269 29. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R,  
270 Genome Project Data Processing S. 2009. The Sequence Alignment/Map format and  
271 SAMtools. *Bioinformatics* 25:2078-9.
- 272 30. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler  
273 D, Gabriel S, Daly M, DePristo MA. 2010. The Genome Analysis Toolkit: a MapReduce  
274 framework for analyzing next-generation DNA sequencing data. *Genome Res* 20:1297-303.
- 275 31. Li H. 2011. A statistical framework for SNP calling, mutation discovery, association mapping  
276 and population genetical parameter estimation from sequencing data. *Bioinformatics* 27:2987-  
277 93.
- 278 32. Hunt M, Mather AE, Sanchez-Buso L, Page AJ, Parkhill J, Keane JA, Harris SR. 2017. ARIBA:  
279 rapid antimicrobial resistance genotyping directly from sequencing reads. *Microb Genom*  
280 3:e000131.
- 281 33. Feuerriegel S, Schleusener V, Beckert P, Kohl TA, Miotto P, Cirillo DM, Cabibbe AM, Niemann  
282 S, Fellenberg K. 2015. PhyResSE: a Web Tool Delineating *Mycobacterium tuberculosis*  
283 Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data. *J Clin Microbiol*  
284 53:1908-14.
- 285 34. Feuerriegel S, Koser CU, Niemann S. 2014. Phylogenetic polymorphisms in antibiotic  
286 resistance genes of the *Mycobacterium tuberculosis* complex. *J Antimicrob Chemother*  
287 69:1205-10.
- 288 35. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, Angeby K, Jureen P,  
289 Moradigaravand D, Parkhill J, Peacock SJ, Schon T, Maurer FP, Walker T, Koser C, Niemann  
290 S. 2020. Phylogenetically informative mutations in genes implicated in antibiotic resistance in  
291 *Mycobacterium tuberculosis* complex. *Genome Med* 12:27.
- 292 36. Lee BM, Harold LK, Almeida DV, Afriat-Jurnou L, Aung HL, Forde BM, Hards K, Pidot SJ,  
293 Ahmed FH, Mohamed AE, Taylor MC, West NP, Stinear TP, Greening C, Beatson SA,  
294 Nuermberger EL, Cook GM, Jackson CJ. 2020. Predicting nitroimidazole antibiotic resistance  
295 mutations in *Mycobacterium tuberculosis* with protein engineering. *PLoS Pathog* 16:e1008287.

296

297



298 **TABLE 1. Observed polymorphisms in F<sub>420</sub> genes and minimal inhibitory concentration values for delamanid.**

No.	Lineage	Country	HIV status	Age at TB diagnosis	Gender	Mutations in the F <sub>420</sub> genes	Treatment	Treatment outcome	MIC mg/L in the micro-dilution
0	H37Rv ATCC 27294	-	-	-	-	Control (wt)	-	-	≤0.015
<b>1</b>	<b>L4.1.2.1</b>	<b>Côte d'Ivoire</b>	<b>Negative</b>	<b>29</b>	<b>Female</b>	<b><i>fgd1</i> Lys270Met</b>	<b>2HRZE, 4RH</b>	<b>Cured</b>	<b>0.5</b>
2	L4.6.2.2	Côte d'Ivoire	Negative	51	Male	<i>ddn</i> C168T	2HRZE, 4RH	Died	≤0.015
3	L2.2.1	Kenya	Positive	40	Male	<i>fgd1</i> T960C	2HRZE, 4RH	Died	≤0.015
4	L2.2.1	Peru	Positive	28	Male	<i>fgd1</i> T960C	2HRZE, 4RH	Unknown	≤0.015
5	L4.3.2	Peru	Negative	21	Male	<i>fbiC</i> C1161T	2HRZE, 4RH	Cured	≤0.015
<b>6</b>	<b>L4.1.2.1</b>	<b>Peru</b>	<b>Positive</b>	<b>45</b>	<b>Male</b>	<b><i>fgd1</i> Lys270Met</b>	<b>2HRZE, 4RH</b>	<b>Unknown</b>	<b>0.03</b>
7	L4.1.2.1	Peru	Positive	36	Male	<i>fbiC</i> G-11A <i>fgd1</i> Lys270Met	2HRZE, 4RH	Unknown	≤0.015
8	L4.1.2	South Africa	Negative	57	Female	<i>fbiA</i> Ile208Val	2HRZE, 4RH	Cured	≤0.015
<b>9</b>	<b>L2.2.1</b>	<b>Thailand</b>	<b>Unknown</b>	<b>76</b>	<b>Male</b>	<b><i>fgd1</i> T960C <i>ddn</i> 85-87del (Tyr29del)</b>	<b>2HRZE, 4RH</b>	<b>Died</b>	<b>&gt;8</b>
<b>10</b>	<b>L1.1.1</b>	<b>Thailand</b>	<b>Negative</b>	<b>42</b>	<b>Male</b>	<b><i>fbiC</i> Ala416Val, Trp678Gly <i>fgd1</i> Arg64Ser, T960C</b>	<b>2HRZE, 4RH</b>	<b>Unknown</b>	<b>0.03</b>

299 Abbreviations: MIC, minimal inhibitory concentration; No, number; L, lineage; wt, wild-type; H, isoniazid; R, rifampicin; Z, pyrazinamide; E, ethambutol.